No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.-Reference-Cited by-同舟云学术

No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.

Published:2021-06 Issue: Volume:51 Page:102875
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Zafar Azra^ORCID,AlShamrani Foziah Jabbar Gossab^ORCID

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference28 articles.

1. Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems;Bargagli;J Neurol,2016

2. Multiple sclerosis;Compston;Lancet,2002

3. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition;Walton;Mult Scle,2020

4. Commentary: global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015;Karikari;Front Neurol,2018

5. Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region;Yamout;Mult Scler J Exp Transl Clin,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study;International Journal of Molecular Sciences;2023-09-27

2. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-02

3. Self‐injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real‐world cohort;Acta Neurologica Scandinavica;2022-01-19